Table 4 Relationship between the willingness toward drug susceptibility genetic studies and the attitudes toward genome studies from Logistic Regression Analysis
Male (n=704 ) | Female (n=769) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Willingness toward drug susceptibility genetic studies | Willingness toward drug susceptibility genetic studies | |||||||||
Yes (n=339) | Neutral or No (n=348) | ORa | 95 % CI | P-value | Yes (n=360) | Neutral or No (n=391) | ORa | 95 % CI | P-value | |
n (%) | n (%) | n (%) | n (%) | |||||||
High awareness of the Nagahama study | 131 (38.9) | 77 (22.5) | 2.06 | 1.40–3.03 | <0.001 | 200 (56.0) | 178 (46.4) | 1.28 | 0.92–1.79 | 0.150 |
Self-rated understanding of terminology | ||||||||||
High | 162 (47.9) | 88 (25.3) | 1 | 117 (32.8) | 67 (17.5) | 1 | ||||
Middle | 120 (35.5) | 124 (35.6) | 0.58 | 0.39–0.87 | 0.008 | 148 (41.5) | 119 (31.2) | 0.81 | 0.53–1.22 | 0.307 |
Low | 56 (16.6) | 136 (39.1) | 0.33 | 0.20–0.54 | <0.001 | 92 (25.8) | 196 (51.3) | 0.35 | 0.22–0.55 | <0.001 |
The use of genetic information is helpful for disease treatment | 311 (94.0) | 241 (71.9) | 3.41 | 1.93–6.01 | <0.001 | 317 (90.1) | 272 (76.0) | 2.51 | 1.54–4.07 | <0.001 |
Concerns | ||||||||||
Financial infusion | 268 (82.5) | 247 (74.6) | 0.98 | 0.60–1.60 | 0.941 | 280 (80.2) | 260 (73.2) | 0.90 | 0.59–1.38 | 0.629 |
Privacy concerns | 199 (60.9) | 197 (59.3) | 0.93 | 0.59–1.45 | 0.739 | 200 (56.7) | 190 (52.9) | 0.94 | 0.63–1.40 | 0.762 |
Discriminations | 139 (42.0) | 147 (44.3) | 0.83 | 0.53–1.28 | 0.289 | 145 (41.2) | 127 (35.7) | 1.17 | 0.78–1.75 | 0.459 |
Unexpected negative effects | 131 (39.7) | 133 (39.9) | 1.09 | 0.70–1.70 | 0.696 | 117(33.1) | 112 (31.1) | 0.97 | 0.63–1.49 | 0.891 |
Cloned human beings | 114 (34.5) | 122 (36.9) | 0.85 | 0.54–1.34 | 0.934 | 143 (40.7) | 137 (38.3) | 1.04 | 0.67–1.61 | 0.872 |
Belief | ||||||||||
Company or government | 161 (49.4) | 137 (41.4) | 1.32 | 0.89–1.94 | 0.167 | 143 (40.7) | 137 (38.3) | 0.89 | 0.61–1.29 | 0.529 |